Note: If IHC reveals that the tumor has the BRAF V600E variant in cases with MSI-H or loss of expression of both MLH1 and PMS2 proteins, a sporadic tumor is likely and there is no need to proceed to genetic testing (STEP 3). The gene discussed is PMS2; the disease is neoplasm.